S. Gourgou-Bourgade

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

Thierry Conroy, Françoise Desseigne, Marc Ychou et al. · New England Journal of Medicine · 2011 · 7.6K citations · Full text

Comparison of Two Neoadjuvant Chemoradiotherapy Regimens for Locally Advanced Rectal Cancer: Results of the Phase III Trial ACCORD 12/0405-Prodige 2

Jean‐Pierre Gérard, D. Azria, S. Gourgou-Bourgade et al. · Journal of Clinical Oncology · 2010 · 747 citations

Impact of FOLFIRINOX Compared With Gemcitabine on Quality of Life in Patients With Metastatic Pancreatic Cancer: Results From the PRODIGE 4/ACCORD 11 Randomized Trial

S. Gourgou-Bourgade, Caroline Mollévi, Françoise Desseigne et al. · Journal of Clinical Oncology · 2012 · 480 citations · Full text

Clinical Outcome of the ACCORD 12/0405 PRODIGE 2 Randomized Trial in Rectal Cancer

Jean‐Pierre Gérard, D. Azria, S. Gourgou-Bourgade et al. · Journal of Clinical Oncology · 2012 · 421 citations · Full text

Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial

Thierry Conroy, Marie‐Pierre Galais, Jean‐Luc Raoul et al. · The Lancet Oncology · 2014 · 416 citations

Surgical Oncology, Esophageal Cancer, Gastrointestinal Oncology +9